Robert Henry, MD

Robert Henry, MD
 

Chief, Center for Metabolic Research
Chief, Section of Endocrinology, Metabolism & Diabetes
Veterans Affairs Healthcare System
Professor of Medicine‚ Department of Medicine
Division of Endocrinology and Metabolism
University of California‚ San Diego

What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D? Video

What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D?

What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D?
Robert Henry, MD

Robert Henry, MD

How do the results and study design of LEADER differ from the CV outcomes study that evaluated lixisenatide in patients with T2D? Was the CV protection seen in LEADER observed in diabetic patients on statins? How does LEADER differ from the EMPA-REG study? Video

How do the results and study design of LEADER differ from the CV outcomes study that evaluated lixisenatide in patients with T2D? Was the CV protection seen in LEADER observed in diabetic patients on statins? How does LEADER differ from the EMPA-REG study?

How do the results and study design of LEADER differ from the CV outcomes study that evaluated lixisenatide in patients with T2D? Was the CV protection seen in LEADER observed in diabetic patients on statins? How does LEADER differ from the EMPA-REG study?
Robert Henry, MD

Robert Henry, MD

What are the implications of the LEADER trial for practitioners at the front lines of diabetes care? And how will it fit into the treatment algorithm? Video

What are the implications of the LEADER trial for practitioners at the front lines of diabetes care? And how will it fit into the treatment algorithm?

What are the implications of the LEADER trial for practitioners at the front lines of diabetes care? And how will it fit into the treatment algorithm?
Robert Henry, MD

Robert Henry, MD

What are we learning about the efficacy and safety of ultra-long-acting insulins such as degludec and U300 glargine? Video

What are we learning about the efficacy and safety of ultra-long-acting insulins such as degludec and U300 glargine?

What are we learning about the efficacy and safety of ultra-long-acting insulins such as degludec and U300 glargine?
Robert Henry, MD

Robert Henry, MD